Pharmaceutical Combination of Angiotensin II Antagonists and Angiotensin I Converting Enzyme Inhibitors
    1.
    发明申请
    Pharmaceutical Combination of Angiotensin II Antagonists and Angiotensin I Converting Enzyme Inhibitors 审中-公开
    血管紧张素II拮抗剂和血管紧张素转换酶抑制剂的药物组合

    公开(公告)号:US20080146639A1

    公开(公告)日:2008-06-19

    申请号:US12035166

    申请日:2008-02-21

    IPC分类号: A61K31/4184 A61P9/00 A61P7/00

    摘要: A method of treatment of indications which can be positively influenced by inhibition of AT1 mediated effects with maintenance of AT2 receptor mediated effects of angiotensin II and by ACE inhibition, thus also increasing bradykinin mediated effects, e.g., to reduce the incidence of stroke, acute myocardial infarction or cardiovascular death, or of indications associated with the increase of AT1 receptors in the subepithelial area or increase of AT2 receptors in the epithelia, comprising coadministration of effective amounts of an angiotensin II antagonist and an ACE inhibitor, pharmaceutical compositions containing an angiotensin II antagonist together with an ACE inhibitor and the use of an angiotensin II antagonist and an ACE inhibitor for the manufacture of corresponding pharmaceutical compositions.

    摘要翻译: 一种治疗适应症的方法,其可以通过维持AT2受体介导的血管紧张素II的作用和通过ACE抑制来抑制AT 1介导的作用而受到积极的影响,因此也 增加缓激肽介导的作用,例如降低卒中发生率,急性心肌梗死或心血管死亡,或与上皮下区域中的AT 1受体增加有关的适应症或AT < 包括共同施用有效量的血管紧张素II拮抗剂和ACE抑制剂,含有血管紧张素II拮抗剂和ACE抑制剂的药物组合物,以及使用血管紧张素II拮抗剂和ACE抑制剂 制造相应的药物组合物。